The world risks a resurgence of the HIV epidemic after international funding fell by nearly a fifth in a single year, UNAIDS has warned in a new report released at the 26th International AIDS Conference in Rio de Janeiro. This latest HIV update 2026 lands as health officials gather for a High-Level Meeting on HIV 2026 to discuss how to keep decades of progress from unraveling.
Background
For nearly two decades, international donors, led overwhelmingly by the United States, funded the bulk of the global HIV response. Washington alone had accounted for roughly 75 percent of international HIV funding before a series of abrupt policy shifts beginning in January 2025 disrupted that support and triggered widespread service cuts.
According to UNAIDS’ new epidemiology of HIV/AIDS data, new HIV infections and AIDS-related deaths are currently at their lowest levels in more than 30 years. Despite that progress, the agency warns the underlying response remains extremely fragile, with the goal of ending AIDS as a public health threat by 2030 now genuinely at risk.
The HIV fact sheet released alongside the report shows 1.2 million people acquired HIV in 2025 alone, and progress across different regions has been deeply uneven. New infections actually rose in three regions and 21 countries last year, reversing gains that had taken years to build.
Details
The core figures behind this year’s Hiv funding cuts are stark. International financing for HIV fell from $8.8 billion in 2024 to $7.3 billion in 2025, an 18 percent drop that UNAIDS says marks the lowest funding level in nearly 20 years. Broader global development assistance fell even further, dropping 23 percent, the largest single-year decline ever recorded.
Reviewing the HIV country statistics behind these numbers shows just how uneven the damage has been. In sub-Saharan Africa, roughly 80 percent of HIV prevention funding came from international aid, meaning the region absorbed a disproportionate share of the cuts. Community-led organizations, which received up to a quarter of foreign HIV assistance in 2024 and reached up to 60 percent of marginalized populations in some countries, are now at risk of losing that support entirely.
The Hiv data on treatment access is equally concerning. Around 9 million of the 41 million people currently living with HIV worldwide are not on treatment, and nearly half of all children living with HIV lacked access to antiretroviral therapy in 2025. If US-supported HIV programs collapse entirely, UNAIDS projects an additional 6 million new infections and 4 million additional AIDS-related deaths could occur between 2025 and 2029.
There is, however, one genuine bright spot amid the funding crisis: a new generation of long-acting HIV prevention medicine, led by the twice-yearly injectable lenacapavir, has shown near-total effectiveness in clinical trials, with more than 99 percent of trial participants remaining HIV negative. The US government’s PEPFAR program has committed to distributing the drug in 8 to 12 high-burden countries in 2026, and Zimbabwe has already begun rolling it out to roughly 46,500 high-risk individuals in its first phase.
Quotes
UNAIDS said in its special report that the international community has entered a period of profound political and financial upheaval that threatens decades of hard-won gains against HIV, warning that without renewed commitment and action, the world risks a genuine resurgence of the epidemic.
UNAIDS Executive Director Winnie Byanyima described the funding gap in blunt terms, calling it not just a funding shortfall but a ticking time bomb, and noting that health workers have been sent home while services have vanished overnight in some of the hardest-hit countries.
A UNAIDS specialist speaking to UN News also flagged a newer concern shaping the current HIV update 2026 landscape, noting that cyberattacks, data breaches, and online harassment targeting HIV-positive individuals have become significant obstacles to prevention and treatment work, making digital security an increasingly central part of the fight against the epidemic.
Impact
The global impact of this funding collapse extends well beyond any single country’s health system. Nations most dependent on international assistance, particularly across sub-Saharan Africa, face the starkest choices, having to decide between scaling back prevention programs or diverting scarce domestic resources away from other health priorities to fill the gap.
The rollout of lenacapavir illustrates a parallel tension defining this year’s HIV response. While the drug represents one of the biggest scientific breakthroughs in HIV prevention in years, high prices and limited manufacturing capacity mean it could remain out of reach for millions of the people who need it most, even as wealthier countries move quickly to expand access.
For children living with HIV, the impact has been especially severe. With 620,000 children under the age of 14 still not on treatment as of the most recent data, and disruptions to pediatric care programs among the hardest hit by recent cuts, health officials warn that hard-won progress in reducing child mortality from AIDS-related causes is now at genuine risk of reversing.
Conclusion
As global health leaders convene for the High-Level Meeting on HIV 2026 and the broader International AIDS Conference in Rio de Janeiro, UNAIDS is urging governments to reaffirm commitments made at recent multilateral summits and restore funding before further damage becomes irreversible. Whether that call translates into renewed financial commitments will likely determine if the world can still meet its 2030 target to end AIDS as a public health threat.
For now, the latest update about HIV paints a picture of a response caught between genuine scientific progress and a funding crisis serious enough to undo three decades of gains. The next several months look like a critical window for the international community to change course.
Frequently Asked Questions
What is the new treatment for HIV in 2026?
The most significant recent advance is lenacapavir, a twice-yearly injectable drug that has shown near-total effectiveness in preventing HIV infection, with clinical trials recording more than 99 percent of participants remaining HIV negative. Approved by the FDA in June 2025 and since greenlit by European regulators, lenacapavir is now being distributed in select high-burden countries through PEPFAR and the Global Fund, with Zimbabwe among the first nations to begin rollout in early 2026. Beyond prevention, researchers have also reported promising early results for a combination injectable treatment regimen using lenacapavir alongside two additional antibody drugs, which could eventually offer people already living with HIV a twice-yearly treatment option instead of daily pills.
Will HIV end in 2030?
Ending AIDS as a public health threat by 2030 remains the official global target set by UNAIDS and endorsed by the United Nations, but the agency’s own 2026 report makes clear that this goal is now at serious risk. While new infections and AIDS-related deaths have fallen to their lowest levels in more than three decades, the sharp funding cuts of 2025, combined with rising infections in several regions, mean the pace of progress needed to hit the 2030 target has significantly slowed. UNAIDS has been explicit that achieving the goal now depends on whether governments restore lost funding and address the deep inequalities in access to prevention and treatment that continue to leave millions of people without care.
What is the HIV strategy 2026?
The current global HIV strategy for 2026 centers on three main pillars: restoring lost international funding, accelerating access to new long-acting prevention tools like lenacapavir, and strengthening community-led service delivery in the hardest-hit regions. UNAIDS has specifically called on wealthier nations to reaffirm the global solidarity commitments made at recent international summits, while also pushing pharmaceutical companies to expand affordable access to breakthrough prevention drugs so they reach low- and middle-income countries rather than remaining concentrated in wealthier markets. The strategy also emphasizes protecting the 95-95-95 testing, treatment, and viral suppression targets that have driven much of the epidemic’s decline over the past decade, even as funding pressures threaten to undo that progress.
